Baseline Lenacapavir Resistance and Capsid Variability in Bulgaria: A Next-Generation Sequencing Study of Newly Diagnosed HIV-1 Infections
Lenacapavir, the first approved HIV-1 capsid inhibitor, is now being introduced for both treatment and pre-exposure prophylaxis, yet the capsid-coding region lies outside the pol fragment examined in routine genotypic resistance testing, and baseline data on capsid variability remain scarce, particularly in epidemics d...